Nature of PDEs

Posphodiesterases (PDEs) are enzymes that pertain to cyclic nucleotide phosphodiesterases. PDEs are degradative enzymes that slice phosphodiester bond in the second messenger molecules, such as those in cAMP (c yclic adenosine monophosphate) or among nucleotides in nucleic acids, and release polynucleotide units and mononucleotides. These PDEs are thought of as vital controllers of signal transduction (a process by which a cell changes one kind of signal or stimulus into another) arbitrated by these second messenger molecules, such as cAMP, as these phosphodiesterases control internalization, longevity, and wave oscillatory magnitude within sub-cellular areas.

Inhibitors of PDE are those that can extend or augment the consequences of biological activities arbitrated by cAMP (cyclic adenosine monophosphate), by retarding their degeneration by PDE. PDE inhibitors are found to be useful in treating coronary heart disease, dementia, depression, schizophrenia, pulmonary arterial hypertension, and multiple sclerosis and rheumatoid arthritis.

Rolipram and its Activities

Rolipram - (4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) - is a selective inhibitor of type IV cyclic AMP phosphodiesterase (PDE), of sub- type PDE IVB. Cyclic AMP denotes cyclic adenosine monophosphate (cAMP), which is a second messenger system of molecules that is utilized by several neurotransmitters and plays a key role in biochemical processes. These inhibitors possess enhanced PDE IV potentiality and better selectivity in contrast to other PDE subtypes.

In animal studies, it is shown that r olipram enhances memory power and improves the intricate workings of nerve cells. It is observed that rolipram has the capability to subdue immune system functionalities. Retardation of phosphodiesterase type IV (PDE IV) effects an enhancement in cyclic adenosine monophosphate (cAMP) availability. Cyclic adenosine monophosphate (cAMP) is a second messenger molecular system in the workings of signal transformation methodologies. Some studies show that rolipram is effective in cognitive behavior in animals.

The present medication treatment for Alzheimer’s disease or other dementias are proving to be less effective. There is need for an effective treatment methodology for age-based cognitive deficiencies. The limitation of activity at only one of several neurotransmitter systems is causing deficient illness management. A different process is to consider second messenger molecular systems that make use of neurotransmitters. By inhibiting PDEs, cAMP signals can be prolonged.

Retardation of brain signal transduction that control neuroplasticity (It refers to brain activity associated with a given function that can move to a different location in the brain) and cell existence is assumed to be the activity responsible for major depressive disorders. Specifically, cAMP-arbitrated signaling seems to have a vital part in the biological and physical manifestations and medication treatment of depression. Enhancing cAMP between nerve cells, either through retardation of type IV phosphodiesterase (PDE IV) which accelerates the hydrolysis of cAMP, or excitation of adrenoceptors, creates antidepressant-like effects.

In a recent study, increased levels of neurotransmitters like norepinephrine, serotonin and histamine have produced enhanced levels of cAMP. This resulted in increased rolipram binding to PDE IV. As a rationalization, it can be said that PDE IV-inhibition induced higher cAMP levels can undo cAMP-arbitrated behavioral deficiencies that are attributed to lower serotonin levels. This reversion of cAMP-arbitrated behavioral deficiencies pertains to the ATD (acute tryptophan depletion) - triggered impairment of object recognition. As rolipram assists many neurotransmitter systems, like those mentioned above, certain behavioral features can be enhanced, which indicates that rolipram is an effective medical management option in depression scenarios.

It is known that the hypothalamic-pituitary-adrenal axis (HPA) is triggered by exogenous as well as endogenous factors that cause adrenal glucocortocoids (hormones produced in adrenal cortex, such as cortisol) to secrete more. In a major depression situation, the extended enhancement of these glucocorticoid concentrations will result in immunization of the central glucocorticoid receptors. These effects may explain the opinion that several features of cellular resistance are activated in depression.

It is shown that the serotonergic deficiencies, i.e., the deficient availability of the neurotransmitter serotonin in the synaptic space, can be reversed by rolipram, the selective PDE IV inhibitor. This PDE IV inhibition mechanism can be utilized in enhancing memory performance. It is also observed that rolipram also may be useful in the treatment of immuno-inflammatory diseases such as hepatitis.

Studies show that selective PDE IV inhibitor rolipram, which is a prospective antidepressant also, displays psychoactive drug activity and generate gastrointestinal side effects such as pyrosis, emesis, and nausea.